Meiji Holdings Co Ltd
TSE:2269

Watchlist Manager
Meiji Holdings Co Ltd Logo
Meiji Holdings Co Ltd
TSE:2269
Watchlist
Price: 3 129 JPY -0.22% Market Closed
Market Cap: 883B JPY
Have any thoughts about
Meiji Holdings Co Ltd?
Write Note

Meiji Holdings Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Meiji Holdings Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Meiji Holdings Co Ltd
TSE:2269
Operating Income
ÂĄ85.3B
CAGR 3-Years
-6%
CAGR 5-Years
-3%
CAGR 10-Years
8%
Yakult Honsha Co Ltd
TSE:2267
Operating Income
ÂĄ61.9B
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
6%
Ajinomoto Co Inc
TSE:2802
Operating Income
ÂĄ147.4B
CAGR 3-Years
7%
CAGR 5-Years
33%
CAGR 10-Years
9%
Kikkoman Corp
TSE:2801
Operating Income
ÂĄ75.2B
CAGR 3-Years
-4%
CAGR 5-Years
14%
CAGR 10-Years
12%
Nissin Foods Holdings Co Ltd
TSE:2897
Operating Income
ÂĄ57.9B
CAGR 3-Years
8%
CAGR 5-Years
21%
CAGR 10-Years
8%
Toyo Suisan Kaisha Ltd
TSE:2875
Operating Income
ÂĄ75B
CAGR 3-Years
31%
CAGR 5-Years
26%
CAGR 10-Years
11%
No Stocks Found

Meiji Holdings Co Ltd
Glance View

Market Cap
864.3B JPY
Industry
Food Products

Meiji Holdings Co., Ltd. has long been a staple in the world of Japanese consumer goods, specifically in the food and pharmaceutical sectors. Established in 2009 as a result of merging Meiji Seika Kaisha, Ltd. and Meiji Dairies Corporation, the company stands as a testament to the power of strategic consolidation, leveraging over a century of expertise from its predecessors. The company's robust product portfolio spans a diverse array of offerings, including dairy products like yogurts and milk, confectioneries like chocolate and candy, as well as nutrition bars and supplements. This triumvirate of product lines allows Meiji Holdings to position itself in both the everyday consumer market and in specialized health-centric industries, exploiting economies of scale and extensive distribution networks that reach far beyond the Japanese archipelago. In the pharmaceutical arena, Meiji Holdings operates under its subsidiary, Meiji Seika Pharma, focusing predominantly on antibacterial drugs, central nervous system treatments, and veterinary products. By integrating research and development with a comprehensive marketing strategy, the company capitalizes on global health trends and regional disease challenges, expanding in markets that emphasize health and dietary improvements. Financially, Meiji Holdings generates revenue by producing goods that tap into both traditional consumer desires and modern nutritional trends. It makes money by introducing high-margin pharmaceutical innovations alongside its well-established consumer brands, thus benefiting from both everyday sales and solutions aimed at pressing global health needs. Together, these strategic components make Meiji Holdings an agile player in a competitive global market, combining heritage with innovation.

Intrinsic Value
4 287.81 JPY
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Meiji Holdings Co Ltd's Operating Income?
Operating Income
85.3B JPY

Based on the financial report for Jun 30, 2024, Meiji Holdings Co Ltd's Operating Income amounts to 85.3B JPY.

What is Meiji Holdings Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
8%

Over the last year, the Operating Income growth was 11%. The average annual Operating Income growth rates for Meiji Holdings Co Ltd have been -6% over the past three years , -3% over the past five years , and 8% over the past ten years .

Back to Top